Inhibitor Therapeutics, Inc.
INTI · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $378 | $326 | $236 | $888 |
| G&A Expenses | $363 | $370 | $438 | $596 |
| SG&A Expenses | $363 | $370 | $438 | $596 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $741 | $696 | $675 | $1,484 |
| Operating Income | -$741 | -$696 | -$675 | -$1,484 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $29 | $36 | $42 | $62 |
| Pre-Tax Income | -$712 | -$660 | -$633 | -$1,422 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$712 | -$660 | -$633 | -$1,422 |
| % Margin | – | – | – | – |
| EPS | -0.004 | -0.004 | -0.004 | -0.008 |
| % Growth | -7.9% | -2.7% | 55.4% | – |
| EPS Diluted | -0.004 | -0.004 | -0.004 | -0.008 |
| Weighted Avg Shares Out | 172,574 | 172,574 | 172,324 | 172,324 |
| Weighted Avg Shares Out Dil | 172,574 | 172,574 | 172,324 | 172,324 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $36 | $42 | $62 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$712 | -$696 | -$675 | -$1,422 |
| % Margin | – | – | – | – |